GlobeNewswire: Intrommune Therapeutics Contains the last 10 of 51 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T01:37:50ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/12/2844737/0/en/Intrommune-Therapeutics-Strengthens-Board-of-Directors-with-Appointments-of-Dr-Jonathan-Rich-and-Hem-Pandya.html?f=22&fvtc=4&fvtv=27952Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya2024-03-12T15:01:08Z<![CDATA[NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board of directors.]]>https://www.globenewswire.com/news-release/2024/02/22/2833802/0/en/Intrommune-Therapeutics-Presents-Supporting-Data-Introducing-a-New-Form-of-Food-Allergy-Treatment.html?f=22&fvtc=4&fvtv=27952Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment2024-02-22T14:34:33Z<![CDATA[OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects]]>https://www.globenewswire.com/news-release/2024/02/06/2824466/0/en/Intrommune-Therapeutics-To-Present-A-New-Form-Of-Allergy-Treatment-At-The-2024-American-Academy-Of-Allergy-Asthma-Immunology-AAAAI-Annual-Meeting.html?f=22&fvtc=4&fvtv=27952Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting2024-02-06T14:34:58Z<![CDATA[New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy]]>https://www.globenewswire.com/news-release/2024/01/08/2805548/0/en/Inimmune-Corporation-and-Intrommune-Therapeutics-announce-a-collaboration-to-advance-a-revolutionary-rapid-long-acting-oral-mucosal-allergy-immunotherapy-for-the-treatment-of-peanu.html?f=22&fvtc=4&fvtv=27952Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy2024-01-08T14:05:57Z<![CDATA[MISSOULA, Mont. and NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical-stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration. Intrommune is advancing a clinical stage oral mucosal therapy for food allergies in allergic individuals. This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its peanut oral mucosal immunotherapy (OMIT), with the rapid desensitization to allergens provided by Inimmune’s clinical stage proprietary immunotherapy. The combination of these two approaches is expected to result in the rapid and long-term relief of allergic symptoms resulting from peanut exposure and would be a game changer for patients suffering with this potentially life-threatening allergy.]]>https://www.globenewswire.com/news-release/2023/11/09/2777585/0/en/Intrommune-Therapeutics-Presents-Positive-Results-of-Phase-1-OMEGA-Study-Investigating-the-Safety-of-INT301-Toothpaste-for-the-Treatment-of-Peanut-Allergy.html?f=22&fvtc=4&fvtv=27952Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy2023-11-09T16:01:11Z<![CDATA[Study met all primary and secondary safety endpoints, demonstrating INT301 was well-toleratedA small subset analysis provided indications of efficacyFull data set to be reported next year, followed by initiation of the Phase 2 clinical trial in a pediatric population]]>https://www.globenewswire.com/news-release/2023/07/25/2710563/0/en/Intrommune-Therapeutics-Completes-Last-Patient-Last-Visit-in-the-Phase-1-OMEGA-Study-for-Peanut-Allergy.html?f=22&fvtc=4&fvtv=27952Intrommune Therapeutics Completes Last Patient Last Visit in the Phase 1 OMEGA Study for Peanut Allergy2023-07-25T13:35:22Z<![CDATA[Full safety and efficacy data presentation planned for Q4 Full safety and efficacy data presentation planned for Q4]]>https://www.globenewswire.com/news-release/2022/10/26/2541990/0/en/Intrommune-Therapeutics-Completes-Enrollment-in-the-Phase-1-OMEGA-Study-for-Peanut-Allergy.html?f=22&fvtc=4&fvtv=27952Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy2022-10-26T13:35:25Z<![CDATA[Observed only mild and transient adverse events, with no use of emergency epinephrine]]>https://www.globenewswire.com/news-release/2022/09/28/2524437/0/en/Intrommune-Expands-and-Strengthens-Senior-Leadership-Team.html?f=22&fvtc=4&fvtv=27952Intrommune Expands and Strengthens Senior Leadership Team2022-09-28T13:35:00Z<![CDATA[Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development]]>https://www.globenewswire.com/news-release/2022/06/22/2467244/0/en/Intrommune-Announces-Expanded-Scope-of-Phase-1-OMEGA-Study-in-Adults-with-Peanut-Allergy.html?f=22&fvtc=4&fvtv=27952Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy2022-06-22T13:31:00Z<![CDATA[Amendment to Extend Study Duration to 48 weeks]]>https://www.globenewswire.com/news-release/2022/06/01/2454642/0/en/Intrommune-Therapeutics-Names-Nandini-Murthy-as-Head-of-Regulatory.html?f=22&fvtc=4&fvtv=27952Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory2022-06-01T17:33:00Z<![CDATA[Ms. Murthy joins the Intrommune Leadership Team and provides the critical regulatory expertise needed to continue development of the company’s innovative platform of food allergy products embedded in fully-functioning toothpaste Ms. Murthy joins the Intrommune Leadership Team and provides the critical regulatory expertise needed to continue development of the company’s innovative platform of food allergy products embedded in fully-functioning toothpaste]]>